Lineage Cell Therapeutics, Inc.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. carries a market capitalization of 99.65B, placing it among publicly traded companies globally. Its enterprise value stands at 84.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lineage Cell Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. has 252.91M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 24.55, and the price-to-book ratio stands at 5.52.

These figures are as of June 30, 2026. The EV/Sales ratio of 21.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 84.93B versus a market cap of 99.65B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. maintains a current ratio of 6.61, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Lineage Cell Therapeutics, Inc. posted a negative return on equity (ROE) of -59.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.75, reflecting losses generated across the asset base. The company generates approximately 50.36M in revenue per employee across its workforce of 77.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Lineage Cell Therapeutics, Inc.'s stock has declined approximately 43.76% over the past 52 weeks. The 50-day moving average sits at 315.67, while the 200-day moving average is 418.47.

Over the twelve months ended June 30, 2026, Lineage Cell Therapeutics, Inc. generated 3.88B in revenue and converted that into -9.56B in net income, yielding earnings per share of -38.27. EBITDA reached -7.74B, while operating income came in at -7.96B.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. holds 15.07B in cash and equivalents against 681.41M in total debt, resulting in a net debt position of -11.07B. Total book value stands at 18.06B, with working capital of 13.32B providing operational flexibility.

Lineage Cell Therapeutics, Inc. produced -7.06B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -170.13M in capital expenditures, free cash flow totaled -7.23B - equivalent to -29.92 per share.

Over the twelve months ended June 30, 2026, Lineage Cell Therapeutics, Inc. posted a gross margin of 99.46, reflecting its pricing power and cost economics. The operating margin of -205.23 and net profit margin of -246.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.59, meaning Lineage Cell Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Lineage Cell Therapeutics, Inc.'s most recent stock split took place on October 31, 1997 with a 1:3 split ratio.

As of June 30, 2026, Lineage Cell Therapeutics, Inc. has an Altman Z-Score of -6.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.